Reagents and methods for use in cancer diagnosis, classification and therapy
AssigneeClarient Diagnostic Services, Inc.
InventorsBrian Z. Ring, Douglas T. Ross, Robert S. Seitz
Life of this patent
Estimating the term…
Abstract
Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
Claims31
A kit comprising a prognostic panel of antibodies that includes:
- a first antibody that binds to SLC7A5;
- and
- a second antibody that binds to a biomarker selected from the group consisting of p53, NDRG1, HTF9C, and CEACAM5.
A kit comprising a prognostic panel of antibodies that includes:
- a first antibody that binds to HTF9C;
- and
- a second antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5.
A kit comprising a prognostic panel of antibodies that includes:
- a first antibody that binds to SLC7A5;
- a second antibody that binds to HTF9C;
- and
- a third antibody that binds to a biomarker selected from the group consisting of p53, NDRG1, and CEACAM5.
A kit comprising a prognostic panel of antibodies that includes:
- a first antibody that binds to SLC7A5;
- a second antibody that binds to HTF9C;
- a third antibody that binds to p53;
- a fourth antibody that binds to NDRG1;
- and
- a fifth antibody that binds to CEACAM5.
A kit comprising a prognostic panel of antibodies, the prognostic panel of antibodies consisting essentially of:
- a first antibody that binds to SLC7A5;
- a second antibody that binds to HTF9C;
- and
- one, two, or three antibodies that each bind to a different biomarker selected from the group consisting of p53, NDRG1, and CEACAM5.
A kit comprising a prognostic panel of antibodies, the prognostic panel of antibodies consisting essentially of:
- a first antibody that binds to SLC7A5;
- a second antibody that binds to HTF9C;
- a third antibody that binds to p53;
- a fourth antibody that binds to NDRG1;
- and
- a fifth antibody that binds to CEACAM5.
Dependencies are inferred from the claim text.